BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Valentino LA. Recombinant FIXFc: a novel therapy for the royal disease? Expert Opinion on Biological Therapy 2011;11:1361-8. [DOI: 10.1517/14712598.2011.603304] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Franchini M. Current management of hemophilia B: recommendations, complications and emerging issues. Expert Review of Hematology 2014;7:573-81. [DOI: 10.1586/17474086.2014.947955] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
2 Sommer JM, Buyue Y, Bardan S, Peters RT, Jiang H, Kamphaus GD, Gray E, Pierce GF. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost 2014;112:932-40. [PMID: 25144892 DOI: 10.1160/TH13-11-0971] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 5.9] [Reference Citation Analysis]
3 Franchini M, Frattini F, Crestani S, Sissa C, Bonfanti C. Treatment of hemophilia B: focus on recombinant factor IX. Biologics 2013;7:33-8. [PMID: 23430394 DOI: 10.2147/BTT.S31582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
4 Simpson ML, Valentino LA. Management of joint bleeding in hemophilia. Expert Rev Hematol 2012;5:459-68. [PMID: 22992238 DOI: 10.1586/ehm.12.27] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
5 Roberts SA, Dong B, Firrman JA, Moore AR, Sang N, Xiao W. Engineering Factor Viii for Hemophilia Gene Therapy. J Genet Syndr Gene Ther 2011;1:S1-006. [PMID: 23565342 DOI: 10.4172/2157-7412.S1-006] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
6 Chen X, Zaro JL, Shen WC. Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opin Drug Metab Toxicol 2012;8:581-95. [PMID: 22428984 DOI: 10.1517/17425255.2012.673585] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
7 Franchini M, Frattini F, Crestani S, Bonfanti C. Haemophilia B: current pharmacotherapy and future directions. Expert Opin Pharmacother 2012;13:2053-63. [PMID: 22946758 DOI: 10.1517/14656566.2012.721780] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
8 Brimble MA, Reiss UM, Nathwani AC, Davidoff AM. New and improved AAVenues: current status of hemophilia B gene therapy. Expert Opinion on Biological Therapy 2015;16:79-92. [DOI: 10.1517/14712598.2015.1106475] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]